TY - JOUR
T1 - Moexipril for treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid
AU - Charatcharoenwitthaya, Phunchai
AU - Talwalkar, Jayant A.
AU - Angulo, Paul
AU - Gossard, Andrea A.
AU - Keach, Jill C.
AU - Petz, Janice L.
AU - Jorgensen, Roberta A.
AU - Lindor, Keith D.
PY - 2010/2
Y1 - 2010/2
N2 - Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.
AB - Blockade of angiotensin II synthesis attenuates hepatic fibrosis in different experimental models of chronic liver injury. We evaluated the safety and efficacy of moexipril, an angiotensin-converting enzyme inhibitor, in patients with primary biliary cirrhosis (PBC) who have had a suboptimal response to ursodeoxycholic acid (UDCA). Twenty PBC patients on UDCA (13-15 mg/kg/day) therapy with an elevation of serum alkaline phosphatase at least twice the upper limit of normal were treated with oral moexipril 15 mg/day for one year. No significant changes in serum alkaline phosphatase (379 ± 32 vs. 379 ± 51), bilirubin (0.8 ± 0.1 vs. 0.9 ± 0.1), aspartate aminotransferase (60 ± 8 vs. 63 ± 9), and Mayo risk score (3.55 ± 0.2 vs. 3.62 ± 0.2) was associated with the treatment. Fatigue and health-related quality of life scores during treatment demonstrated a trend toward improvement. Moexipril was not clinically beneficial to PBC patients responding suboptimally to UDCA.
KW - Angiotensin-converting enzyme inhibitor
KW - Primary biliary cirrhosis
KW - Treatment
KW - Ursodeoxycholic acid
UR - http://www.scopus.com/inward/record.url?scp=76849086042&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=76849086042&partnerID=8YFLogxK
U2 - 10.1007/s10620-009-0744-1
DO - 10.1007/s10620-009-0744-1
M3 - Article
C2 - 19255851
AN - SCOPUS:76849086042
SN - 0163-2116
VL - 55
SP - 476
EP - 483
JO - Digestive diseases and sciences
JF - Digestive diseases and sciences
IS - 2
ER -